Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766199 | 0.88 | ALDH1A1 (0.42) | NLRP3MEN1KMT2APTPN1KDM4E | |
| SCHEMBL3618251 | 0.83 | ELANE (0.33) | LMNANLRP3MEN1KMT2APTPN1 | |
| SCHEMBL3624434 | 0.80 | NPSR1 (0.40) | LMNANLRP3PKMHTTPTPN1 | |
| SCHEMBL5766878 | 0.79 | CCNE2 (0.42) | KDM4EMAPTALDH1A1 | |
| SCHEMBL5764891 | 0.78 | KDM4E (0.35) | KDM4EMAPTALDH1A1CA12CA2 | |
| SCHEMBL3624777 | 0.77 | HSD17B10 (0.39) | HTTMEN1KMT2AKDM4EMAPT | |
| SCHEMBL5765951 | 0.77 | KDM4E (0.32) | LMNAKDM4EMAPT | |
| SCHEMBL5765490 | 0.76 | KDM4E (0.37) | LMNAKMT2AKDM4EMAPTCA12 | |
| SCHEMBL5766496 | 0.76 | ALDH1A1 (0.35) | KDM4EMAPTALDH1A1 | |
| SCHEMBL5679654 | 0.76 | HDAC3 (0.35) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267796-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2077122-A1 | THERAPEUTIC AGENTS FOR IRRITABLE BOWEL SYNDROME | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267796-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | SLC10A2, ADORA3, HRH2 | LMNA 4307/4885NLRP3 1311/4885PKM 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.